phrykt

Idexx Laboratories Inc /De (IDXX): who owns it and who trades it

As of Nov 16, 2026, IDXX insiders reported 53 open-market sales worth $58.4M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jonathan Jay Mazelsky (CEO), with $33M. 9 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Idexx Laboratories

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns IDXX

1,297 funds and institutions reported IDXX shares worth $39.4B at the end of Q2 2026, about 95% of the company. The largest holder is BlackRock, Inc. with 10.4%.

Funds and institutions (13F) 95%Everyone else 5%

10 largest owners, by share of the company

BlackRock, Inc.10.4%
Vanguard Capital Management LLC6.5%
Vanguard Portfolio Management LLC4.9%
State Street Corp4.8%
Invesco Ltd.4.6%
Geode Capital Management, LLC3.2%
Bamco Inc2.5%
Morgan Stanley1.7%
Bank of New York Mellon Corp1.5%
Arrowstreet Capital, Limited Partnership1.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.8.17M10.36%$4.3B-2%
Vanguard Capital Management LLC5.15M6.53%$2.7B-1%
Vanguard Portfolio Management LLC3.90M4.94%$2.1B-0%
State Street Corp3.75M4.75%$2B+2%
Invesco Ltd.3.61M4.58%$1.9B+115%
Geode Capital Management, LLC2.56M3.25%$1.3B-4%
Bamco Inc1.98M2.51%$1B+21%
Morgan Stanley1.36M1.72%$714M+3%
Bank of New York Mellon Corp1.19M1.51%$628M-21%
Arrowstreet Capital, Limited Partnership1.07M1.35%$562M+27%
Fundsmith LLP1.02M1.29%$537M-30%
Blair William & Co918,5561.16%$484M-3%
Northern Trust Corp918,1371.16%$483M+1%
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC911,4891.16%$480M+5%
FMR LLC (Fidelity)822,6431.04%$433M+191%
American Century Companies Inc808,3581.02%$426M+35%
Capital Research Global Investors789,1111.00%$415M+1%
JPMorgan Chase & Co755,7910.96%$405M–
Principal Financial Group Inc743,2460.94%$391M-16%
Goldman Sachs Group Inc738,7080.94%$389M+3%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, IDXX insiders reported $0 of open-market purchases and $58.4M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$58.4M
53 trades, 9 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Nov 4, 2026
Filed Nov 5, 2026

Purchases and sales by month

$28.7M$28.7MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 4, 2026Daniel M JuniusDirectorSale700$705.78$494KForm 4
Nov 4, 2026Daniel M JuniusDirectorSale500$701.68$351KForm 4
Nov 4, 2026Michael LaneVice presidentSale243$687.85$167KForm 4
Nov 4, 2026Michael LaneVice presidentSale2,059$689.70$1.4MForm 4
Nov 4, 2026Michael LaneVice presidentSale1,677$687.46$1.2MForm 4
Nov 4, 2026Jonathan Jay MazelskyChairSale1,945$698.26$1.4MForm 4
Nov 4, 2026Jonathan Jay MazelskyChairSale4,075$699.33$2.8MForm 4
Nov 4, 2026Jonathan Jay MazelskyChairSale1,667$700.33$1.2MForm 4
Nov 4, 2026Jonathan Jay MazelskyChairSale4,540$701.36$3.2MForm 4
Nov 4, 2026Jonathan Jay MazelskyChairSale2,136$702.21$1.5MForm 4
Nov 4, 2026Jonathan Jay MazelskyChairSale3,950$703.45$2.8MForm 4
Nov 4, 2026Jonathan Jay MazelskyChairSale240$705.59$169KForm 4
Nov 4, 2026Jonathan Jay MazelskyChairSale840$707.00$594KForm 4
Nov 4, 2026Jonathan Jay MazelskyChairSale1,840$707.84$1.3MForm 4
Nov 4, 2026Jonathan Jay MazelskyChairSale1,300$709.00$922KForm 4
Nov 4, 2026Jonathan Jay MazelskyChairSale1,501$710.12$1.1MForm 4
Nov 4, 2026Jonathan Jay MazelskyChairSale775$711.31$551KForm 4
Nov 4, 2026Jonathan Jay MazelskyChairSale331$711.95$236KForm 4
Nov 4, 2026Sharon E. UnderbergVice presidentSale6,348$688.25$4.4MForm 4
Nov 4, 2026Sharon E. UnderbergVice presidentSale1,503$689.05$1MForm 4
Nov 4, 2026Sharon E. UnderbergVice presidentSale1,055$690.02$728KForm 4
Sep 4, 2026Lawrence D KingsleyDirectorSale2,203$532.08$1.2MForm 4
Mar 3, 2026Nimrata HuntVice presidentSale1,758$634.57$1.1MForm 4
Feb 26, 2026Jonathan Jay MazelskyCEOSale2,860$657.84$1.9MForm 4
Feb 26, 2026Jonathan Jay MazelskyCEOSale1,095$651.49$713KForm 4
Feb 26, 2026Jonathan Jay MazelskyCEOSale1,281$650.67$834KForm 4
Feb 26, 2026Jonathan Jay MazelskyCEOSale2,589$663.04$1.7MForm 4
Feb 26, 2026Jonathan Jay MazelskyCEOSale1,000$662.16$662KForm 4
Feb 26, 2026Jonathan Jay MazelskyCEOSale1,200$661.10$793KForm 4
Feb 26, 2026Jonathan Jay MazelskyCEOSale2,859$659.75$1.9MForm 4
Feb 26, 2026Jonathan Jay MazelskyCEOSale1,669$652.49$1.1MForm 4
Feb 26, 2026Jonathan Jay MazelskyCEOSale1,171$653.68$765KForm 4
Feb 26, 2026Jonathan Jay MazelskyCEOSale1,111$654.63$727KForm 4
Feb 26, 2026Jonathan Jay MazelskyCEOSale1,488$655.85$976KForm 4
Feb 26, 2026Jonathan Jay MazelskyCEOSale1,343$656.85$882KForm 4
Feb 26, 2026Jonathan Jay MazelskyCEOSale3,660$658.92$2.4MForm 4
Feb 26, 2026Nimrata HuntVice presidentSale2,693$661.54$1.8MForm 4
Feb 17, 2026Michael G EricksonVice presidentSale456$623.76$284KForm 4
Feb 17, 2026Michael G EricksonVice presidentSale204$625.24$128KForm 4
Feb 17, 2026Michael G EricksonVice presidentSale1,288$626.26$807KForm 4
Feb 17, 2026Michael G EricksonVice presidentSale2,694$628.22$1.7MForm 4
Feb 17, 2026Michael G EricksonVice presidentSale689$629.09$433KForm 4
Feb 17, 2026Michael G EricksonVice presidentSale40$629.86$25.2KForm 4
Feb 17, 2026Sophie V. VandebroekDirectorSale945$628.65$594KForm 4
Feb 17, 2026Sophie V. VandebroekDirectorSale519$628.56$326KForm 4
Feb 10, 2026George FennellVice presidentSale1,130$643.00$727KForm 4
Feb 10, 2026George FennellVice presidentSale397$644.02$256KForm 4
Feb 10, 2026George FennellVice presidentSale2,161$645.25$1.4MForm 4
Feb 10, 2026George FennellVice presidentSale1,060$647.21$686KForm 4
Feb 10, 2026George FennellVice presidentSale966$648.78$627KForm 4
Feb 10, 2026George FennellVice presidentSale2,809$649.26$1.8MForm 4
Feb 10, 2026George FennellVice presidentSale40$650.32$26KForm 4
Feb 10, 2026George FennellVice presidentSale2,782$646.23$1.8MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Jonathan Jay MazelskyPresident and CEO, Director–$33MNov 4, 2026
George FennellExecutive Vice President–$7.3MFeb 10, 2026
Sharon E. UnderbergEVP, GC & Corporate Secretary–$6.1MNov 4, 2026
Michael G EricksonExecutive Vice President–$3.4MFeb 17, 2026
Nimrata HuntExecutive Vice President–$2.9MMar 3, 2026
Michael LaneExecutive Vice President–$2.7MNov 4, 2026
Lawrence D KingsleyDirector–$1.2MSep 4, 2026
Sophie V. VandebroekDirector–$920KFeb 17, 2026
Daniel M JuniusDirector–$845KNov 4, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

IDXX short interest

Low short interest. 3.0% of IDXX shares are sold short: about 1 share in 33. Over the last 12 reports the number of shares short went up 17%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 2.35M IDXX shares were sold short, 3.0% of the shares outstanding, up 22.0% from the report before. At the average daily volume of 529,434 shares, buying them all back would take about 4.5 trading days (days to cover).

Shares short, % of all shares

2.99%May 15Oct 303.07%

Days to cover

4.5May 15Oct 304.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20262.35M2.99%+22%529,4344.5
Oct 15, 20261.93M2.45%-1%532,5823.6
Sep 30, 20261.94M2.46%+1%496,2673.9
Sep 15, 20261.92M2.43%-8%509,0733.8
Aug 31, 20262.09M2.66%+8%481,2254.3
Aug 14, 20261.94M2.46%+1%736,8982.6
Jul 31, 20261.93M2.45%-8%486,8154.0
Jul 15, 20262.10M2.66%+8%702,9423.0
Jun 30, 20261.94M2.46%-9%770,2182.5
Jun 15, 20262.14M2.71%-2%569,5133.8
May 29, 20262.18M2.76%+8%649,5873.4
May 15, 20262.02M2.56%-3%667,4333.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded IDXX

Since Nov 17, 2024, 4 members of Congress reported 11 purchases and 6 sales of IDXX. The latest was a sale by April McClain Delaney on Jan 13, 2026, reported Feb 2, 2026.

Purchases 11Sales 6

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
Jan 13, 2026April McClain Delaney (D-MD)Sale$1K–$15KChildFeb 2, 2026Report
Oct 16, 2025April McClain Delaney (D-MD)Partial sale$1K–$15KChildNov 4, 2025Report
Sep 4, 2025Byron Donalds (R-FL)Purchase$1K–$15KSelfOct 7, 2025Report
Sep 4, 2025Byron Donalds (R-FL)Purchase$1K–$15KSpouseOct 7, 2025Report
Aug 7, 2025April McClain Delaney (D-MD)Partial sale$1K–$15KChildSep 2, 2025Report
Jul 9, 2025April McClain Delaney (D-MD)Partial sale$1K–$15KChildAug 5, 2025Report
May 15, 2025Robert P. Bresnahan, Jr. (R-PA)Purchase$1K–$15KSelfJun 9, 2025Report
May 12, 2025Jefferson Shreve (R-IN)Sale$100K–$250KSelfJun 22, 2025Report
Apr 9, 2025April McClain Delaney (D-MD)Purchase$1K–$15KChildMay 2, 2025Report
Apr 8, 2025Robert P. Bresnahan, Jr. (R-PA)Sale$1K–$15KSelfApr 28, 2025Report
Apr 7, 2025Jefferson Shreve (R-IN)Purchase$50K–$100KSelfMay 8, 2025Report
Apr 7, 2025April McClain Delaney (D-MD)Purchase$1K–$15KChildMay 2, 2025Report
Apr 4, 2025April McClain Delaney (D-MD)Purchase$1K–$15KChildMay 2, 2025Report
Apr 1, 2025April McClain Delaney (D-MD)Purchase$1K–$15KChildMay 2, 2025Report
Mar 14, 2025April McClain Delaney (D-MD)Purchase$1K–$15KChildApr 2, 2025Report
Mar 13, 2025Jefferson Shreve (R-IN)Purchase$15K–$50KSelfApr 11, 2025Report
Feb 25, 2025Robert P. Bresnahan, Jr. (R-PA)Purchase$1K–$15KSelfMar 27, 2025Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

Idexx Laboratories company events

Idexx Laboratories filed 8 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 2, 2026.

  1. Nov 2, 2026ResultsReleased financial results. Filing
  2. Aug 4, 2026ResultsReleased financial results. Filing
  3. May 15, 2026VoteReported shareholder vote results. Filing
  4. May 5, 2026ResultsReleased financial results. Filing
  5. Mar 26, 2026LeadershipIDEXX Laboratories, Inc. and Nimrata Hunt, PhD, Executive Vice President, Global Strategy and Commercial, mutually agreed that Dr. Hunt will cease serving in her current role effective on April 13, 2026 and will continue to provide advisory services on an as-needed basis until July 13, 2026. Filing
  6. Feb 13, 2026LeadershipMs. M. Anne Szostak provided IDEXX Laboratories, Inc. notice of her intention to retire from the Board of Directors effective immediately following the Company’s 2026 Annual Meeting of Stockholders to be held on May 12, 2026. Filing
  7. Feb 2, 2026ResultsReleased financial results. Filing
  8. Jan 13, 2026LeadershipReported a change among its top officers or directors, or their pay. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Idexx Laboratories financials

Famous investors that hold IDXX

9 of the 50 well-known investors we track reported holding IDXX in their latest 13F filing. The largest position is Terry Smith's, worth $373M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Terry Smith · FundsmithQ3 2026714,883$373M2.9%-30%
Israel Englander · Millennium ManagementQ3 2026306,290$160M0.1%+288%
Steve Cohen · Point72 Asset ManagementQ3 2026173,958$90.8M0.2%-34%
Jim Simons · Renaissance TechnologiesQ3 2026109,644$57.3M0.1%-0%
Ken Griffin · Citadel AdvisorsQ3 2026101,626$53.1M0.0%+162%
Ray Dalio · Bridgewater AssociatesQ3 202638,921$20.3M0.1%+16%
Larry Robbins · Glenview Capital ManagementQ3 20261,200$627K0.0%New
Ken Fisher · Fisher Asset ManagementQ3 2026521$272K0.0%New
Bill Nygren · Harris Associates (Oakmark)Q3 2026455$238K0.0%No change

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named IDXX in the last 120 days.

FiledHolderFormStake
Oct 30, 2026Vanguard Portfolio Management13G5.0%
Oct 30, 2026Vanguard Portfolio Management13G5.0%

Questions about Idexx Laboratories Inc /De (IDXX) stock

Who owns the most IDXX stock?

The largest reported owner of Idexx Laboratories Inc /De (IDXX) is BlackRock, Inc., with 10.4% of the company. In total, 1,297 funds and institutions reported holding IDXX at the end of Q2 2026, together about 95% of the shares. See the largest owners.

Are IDXX insiders buying or selling?

In the last 12 months, IDXX insiders reported no open-market purchases and 53 sales worth $58.4M. The latest trade was on Nov 4, 2026. See every trade.

What is the short interest in IDXX?

As of Oct 30, 2026, 2.35M IDXX shares were sold short, 3.0% of the shares outstanding, up 22.0% from the report before. At the average daily volume of 529,434 shares, buying them all back would take about 4.5 trading days (days to cover). See the history.

Have members of Congress traded IDXX?

Yes. 4 members of Congress reported 11 purchases and 6 sales of IDXX since Nov 17, 2024. The latest was reported on Feb 2, 2026. See the trades.

Which famous investors hold IDXX?

9 of the 50 well-known investors we track reported IDXX in their latest 13F filing, including Terry Smith, Israel Englander, Steve Cohen. The largest position is worth $373M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.